Current Colorectal Cancer Reports

, Volume 1, Issue 1, pp 27–33 | Cite as

Optimizing adjuvant therapy for colon cancer: Ongoing investigations

  • Hanna Kelly
  • Bert H. O’Neil
  • Richard M. Goldberg
Article

Abstract

In 2004, oxaliplatin plus 5-fluorouracil (5FU) and leucovorin (LV) supplanted 5FU/LV as the standard of care for adjuvant therapy of node-positive colon cancer. Data from recently presented phase III clinical trials fail to show a similar benefit for adjuvant irinotecan-5FU/LV over 5FU/LV alone. Current investigations focus on further refining the optimal combination chemotherapy regimen, and incorporating biologic agents into adjuvant therapy of stage II and III colon cancer. In the future, stage-independent prognosticators and markers predictive of chemotherapy response and toxicity may allow for patient-specific selection of more effective and less toxic adjuvant therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wolmark N, Fisher B, Rockette H, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP C-01. J Natl Cancer Inst 1988, 80:30–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Laurie JA, Moertel CG, Fleming TR, et al.: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 7:1447–1456.PubMedGoogle Scholar
  3. 3.
    Windle R, Bell PR, Shaw D: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987, 74:569–572.PubMedCrossRefGoogle Scholar
  4. 4.
    Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352–358.PubMedCrossRefGoogle Scholar
  5. 5.
    Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321–326.PubMedGoogle Scholar
  6. 6.
    Francini G, Petrioli R, Lorenzini L, et al.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994, 106:899–906.PubMedGoogle Scholar
  7. 7.
    O’Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246–250.PubMedGoogle Scholar
  8. 8.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345:939.Google Scholar
  9. 9.
    Taal BG, Van Tinteren H, Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001, 85:1437–1443.PubMedCrossRefGoogle Scholar
  10. 10.
    O’Connell MJ, Laurie JA, Kahn M, et al.: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295–300.PubMedGoogle Scholar
  11. 11.
    Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Breast and Bowel Project C-03. J Clin Oncol 1993, 11:1879–1887.PubMedGoogle Scholar
  12. 12.
    Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from the National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553–3559.PubMedGoogle Scholar
  13. 13.
    Wolmark N, Bryant J, Smith R, et al.: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Breast and Bowel Project C-05. J Natl Cancer Inst 1998, 90:1810–1816.PubMedCrossRefGoogle Scholar
  14. 14.
    QUASAR Collaborative Group: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000, 355:1588–1596.CrossRefGoogle Scholar
  15. 15.
    Porschen R, Bermann A, Loffler T, et al.: Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001, 19:1787–1794.PubMedGoogle Scholar
  16. 16.
    Haller DG, Catalano PJ, MacDonald JS, Mayer RJ: Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five year final report of Int-0089. Proc Am Soc Clin Oncol 1998, 17:256a.Google Scholar
  17. 17.
    Twelves C, Wong A, Nowacki M, et al.: Updated efficacy findings from the X-ACT phase III trial of capecitabine vs. bolus 5-FU/LV as adjuvant therapy for patients with Dukes’ C colon cancer [abstract]. J Clin Oncol 2005, 23:251s.Google Scholar
  18. 18.
    Andre T, Colin P, Louvet C, et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896–2903.PubMedCrossRefGoogle Scholar
  19. 19.
    Poplin EA, Benedetti JK, Estes NC, et al.: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high risk stage II colon cancer. J Clin Oncol 2005, 23:1819–1825.PubMedCrossRefGoogle Scholar
  20. 20.
    Andre T, Quinaux E, Louvet C, et al.: Updated results at 6 year of the GERCOR C96.1 a phase III study comparing LV5FU2 to montly 5FU-leucovorin as adjuvant treatment for Dukes B2 and C colon cancer patients [abstract]. J Clin Oncol 2005, 23:250s.Google Scholar
  21. 21.
    Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil- based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797–1806.PubMedCrossRefGoogle Scholar
  22. 22.
    Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.PubMedGoogle Scholar
  23. 23.
    Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.PubMedCrossRefGoogle Scholar
  24. 24.
    Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of Fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229–237.PubMedCrossRefGoogle Scholar
  26. 26.
    André T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. The MOSAIC trial showed a 23% reduction in the risk of recurrence from FOLFOX over 5FU/LV, making FOLFOX the standard of care for adjuvant therapy of colon cancer.PubMedCrossRefGoogle Scholar
  27. 27.
    de Gramont A, Boni C, Navarro M, et al.: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol 2005, 23:246s.Google Scholar
  28. 28.
    Wolmark N, Wieand S, Kuebler JP, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07 [abstract]. J Clin Oncol 2005, 23:246a. C-07 confirmed the benefit of oxaliplatin in adjuvant therapy of colon cancer, first demonstrated by the MOSIAC trial.Google Scholar
  29. 29.
    Saltz LB: Adjuvant therapy of colon cancer: where are we now? Presented at the American Society of Clinical Oncology: Orlando, FL; May 16, 2005. http://www.asco.org/ac/ 1,1003,_12-002803,00.aspGoogle Scholar
  30. 30.
    Smith RE, Colangelo L, Wieand S, et al.: The occurrence of severe enteropathy among patients with stage II/III resected colon cancer treated with 5-fluorouracil/leucovorin plus oxaliplatin: September 2003 update [abstract]. GI Cancers Symposium 2004. http://www.asco.org/ac/1,1003,_12-002627-00_18-0027-00_19-00247,00.aspGoogle Scholar
  31. 31.
    Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801–3807.PubMedGoogle Scholar
  32. 32.
    Schmoll HJ, Tabernero J, Nowacki M, et al.: Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients with stage III colon cancer [abstract]. J Clin Oncol 2005, 23:251s.Google Scholar
  33. 33.
    Saltz LB, Niedzwiecki D, Hollis D, et al.: Irinotecan plus fluorouracil/ leucovorin versus fluorouracil/leucovorin alone in stage III colon cancer (intergroup trial CALGB C89803) [abstract]. Proc Am Soc Clin Oncol 2004, 23:246. One of three recent phase III trials that failed to meet its primary endpoint of improved DFS from adjuvant irinotecan/5FU/LV over 5FU/LV.Google Scholar
  34. 34.
    Van Cutsem E, Labianca R, Hossfeld D, et al.: Randomized phase III trial comparing infused irinotecan/5-fluorouracil(5-FU)/folinic acid(FA) versus 5-FU/FA in stage III colon cancer patients [abstract]. J Clin Oncol 2005, 23:1090s. One of three recent phase III trials that failed to meet its primary endpoint of improved DFS from adjuvant irinotecan/5FU/LV over 5FU/LV.Google Scholar
  35. 35.
    Ychou M, Raoul JL, Douillard JY, et al.: A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) [abstract]. J Clin Oncol 2005, 23:246s.Google Scholar
  36. 36.
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60–65.PubMedCrossRefGoogle Scholar
  37. 37.
    US Food and Drug Administration: 2004 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. http://www.fda.gov/medwatch/SAFETY/2004/ safety04.htm#avastinGoogle Scholar
  38. 38.
    Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C- 01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.PubMedGoogle Scholar
  39. 39.
    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356–1363.Google Scholar
  40. 40.
    Gray RG, Barnwell J, Hills R, et al.: QUASAR: a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients [abstract]. J Clin Oncol 2004, 22:3501.Google Scholar
  41. 41.
    Hickish T, Boni M, Navarro M, et al.: FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial [abstract]. Proc Am Soc Clin Oncol 2004, 23:275.Google Scholar
  42. 42.
    Benson AB, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408–3419.PubMedCrossRefGoogle Scholar
  43. 43.
    Sargent DJ, Wieand S, Benedetti R, et al.: Disease-free survival vs. overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials [abstract]. Proc Am Soc Clin Oncol 2004, 23:246.Google Scholar
  44. 44.
    Sargent DJ: Endpoints for colon adjuvant clinical trials, recommendations based on individual patient data from 20898 patients and 18 randomized trials [abstract]. J Clin Oncol 2005, 23:249s.CrossRefGoogle Scholar
  45. 45.
    Kern SE, Fearon ER, Tersmette KW, et al.: Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA 1989, 261:3099–3103.PubMedCrossRefGoogle Scholar
  46. 46.
    Fearon ER, Cho KR, Nigro JM, et al.: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990, 247:49–56.PubMedCrossRefGoogle Scholar
  47. 47.
    Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816–819.PubMedCrossRefGoogle Scholar
  48. 48.
    Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812–816.PubMedCrossRefGoogle Scholar
  49. 49.
    Lothe RA, Peltomaki P, Meling GI, et al.: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993, 53:5849–5852.PubMedGoogle Scholar
  50. 50.
    Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69–77.PubMedCrossRefGoogle Scholar
  51. 51.
    Elsaleh H, Shannon B, Iacopetta B: Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy. Gastroenterology 2001, 120:1309–1310.PubMedCrossRefGoogle Scholar
  52. 52.
    Elsaleh H, Iacopetta B: Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001, 1:104-109.PubMedGoogle Scholar
  53. 53.
    Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247–257.PubMedCrossRefGoogle Scholar
  54. 54.
    Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictibe marker validation in cancer treatment trials. J Clin Oncol 2005, 23:2020–2027.PubMedCrossRefGoogle Scholar
  55. 55.
    Iwao-Koizumi K, Matoba R, Ueno N, et al.: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422–431.PubMedCrossRefGoogle Scholar
  56. 56.
    Iyer L, Das S, Janisch L, et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002, 2:43–47.PubMedCrossRefGoogle Scholar
  57. 57.
    Sloan JA, McLeod H, Sargent DJ, et al.: Preliminary evidence of relationship between genetic markers and oncology patient quality of life [abstract]. J Clin Oncol 2004, 22:2.CrossRefGoogle Scholar
  58. 58.
    Köhne C-H, Wils J, Lorenz M, et al.: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003, 21:3721–3728.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Hanna Kelly
  • Bert H. O’Neil
  • Richard M. Goldberg
    • 1
  1. 1.Division of Hematology-Oncology, Department of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations